Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04884243
Other study ID # CBT-CS102
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date September 5, 2021
Est. completion date August 17, 2023

Study information

Verified date August 2023
Source Cloudbreak Therapeutics, LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

STUDY DESIGN Structure: Multicenter, randomized, double-masked, vehicle-controlled, parallel group study. Duration: 3 months of TID treatment. Treatment Groups, Dosing, and Treatment Regimen: Study Treatment: CBT-006 topical ophthalmic solution Control Treatment: CBT-006 vehicle


Description:

Structure: Multicenter, randomized, double-masked, vehicle-controlled, parallel group study. Duration: 3 months of TID treatment. Treatment Groups, Dosing, and Treatment Regimen: Study Treatment: CBT-006 topical ophthalmic solution Control Treatment: CBT-006 vehicle


Recruitment information / eligibility

Status Completed
Enrollment 92
Est. completion date August 17, 2023
Est. primary completion date August 17, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnosed with MGD in both eyes and meet the following: 1. Ocular discomfort Score (ODS) = 2 2. Visual Analog Scale (VAS) level is 35-90% for at least 1 of the 7 categories 3. Total Cornea staining grade = 3 4. Total meibum quality score (MQS) is between 6-17 from the sum of the 6 lower eyelid central glands in at least one lower eyelid 5. TBUT = 5 s 6. Schirmer I Test (anaesthetized) = 5 mm/5 min in study eye 7. BCVA LogMAR = +0.7 in each eye - All patients of both genders = 18 years - Willing to withhold the use of artificial tears and lubricants during the treatment phase; - Able to provide written informed consent and comply with study assessments for the full duration of the study. Exclusion Criteria: - Uncontrolled systemic disease in the opinion of the Investigator - Active allergies with symptoms that may confound the data, active ocular infection requiring treatment, or ocular surface inflammatory disease unrelated to MGD or DED, including chalazion, inflamed pinguecula, and viral illness - History of ocular herpes disease in either eye - Incisional ocular surgery within 6 months or ocular laser surgery within 3 months - Use of topical treatment of the eye/eyelid with antibiotics, NSAIDS, or vasoconstrictors to treat MGD or DED within 14 days of screening; steroids, cyclosporin A or lifitegrast within 28 days of screening - Current or anticipated use of other topical ophthalmic medications in the study eye. (Patients must have discontinued the use of ophthalmic medications in the study eye for at least 2 weeks prior to the screening visit, the use of diagnostic medications as part of the eye exam prior to screening and artificial tears is allowed.) - Anticipated wearing of contact lenses during any portion of the study. (Patients, who wear soft contact lenses should discontinue wearing them at least 3 days prior to screening visit. Patients wearing rigid gas permeable or hard contact lenses should discontinue wearing them at least 3 weeks prior to screening visit.) - Active rosacea involving the eyelids within 60 days of screening - Current enrollment in an investigational drug or device study or participation in such a study within 30 days prior to entry into this study - Any condition or situation which, in the investigator's opinion, may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient's participation in the study - Female patients who are pregnant, nursing, or planning a pregnancy during the study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
CBT-006
ophthalmic solution

Locations

Country Name City State
United States Eye Research Foundation Newport Beach California

Sponsors (1)

Lead Sponsor Collaborator
Cloudbreak Therapeutics, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary IOP of Study Eye Related to Safety Intraocular Pressure of study eye related to safety 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT05062564 - Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye N/A
Active, not recruiting NCT04425551 - Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction N/A
Terminated NCT02596919 - Fast Infrared Meibography (Photography) N/A
Completed NCT01207752 - The Efficacy of an Ocular Emulsion in Meibomian Gland Dysfunction N/A
Completed NCT05162261 - to Evaluate the Effectiveness and Safety of the Tixel® , VS LipiFlow® in the Treatment of Meibomian Gland Dysfunction N/A
Recruiting NCT06064071 - Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD N/A
Completed NCT03652051 - A Multicenter Study Evaluating AZR-MD-001 in Patients With Meibomian Gland Dysfunction and Evaporative Dry Eye Disease (DED) Phase 2
Recruiting NCT03767530 - Efficacy and Safety of Thermic Devices in the Treatment of Meibomian Gland Dysfunction N/A
Active, not recruiting NCT05577910 - Vectored Thermal Pulsation, Intense Pulsed Light, and Eyelid Warm Compress Therapies for MGD N/A
Completed NCT04889950 - Clinical Study to Evaluate the Safety and Effectiveness of The Tixel Fractional System in the Treatment of Meibomian Gland Disfunction N/A
Recruiting NCT06004895 - Mechanisms of Light-based Therapies for Dry Eye Disease N/A
Completed NCT04147962 - Intense Pulsed Light in Meibomian Gland Dysfunctions
Completed NCT02256969 - Intraductal Meibomian Gland Probing Trial Phase 4
Recruiting NCT05089591 - Intense Pulsed Light in Meibomian Gland Dysfunction N/A
Completed NCT04500821 - Evaluation of the LipiFlow System With a New Activator N/A
Completed NCT03318874 - Optimization of the Treatment of Dry Eye Disease Caused by Meibomian Gland Dysfunction Phase 4
Completed NCT06278584 - iLux Treatment for Meibomian Gland Dysfunction N/A
Recruiting NCT04052841 - Morphological Analysis of Meibomian Glands N/A
Completed NCT05028491 - The Influence of Meibomian Gland Expression on Corneal Aberrations in MGD Patients
Completed NCT03617315 - Crosslinked Hyaluronic Acid With Liposomes and Crocin in Dry Eye N/A